Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on APTO. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a report on Friday, June 14th. Canaccord Genuity Group lowered their price target on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a research note on Thursday, May 16th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Aptose Biosciences has an average rating of Moderate Buy and an average price target of $14.80.

Aptose Biosciences Trading Down 7.5 %

APTO stock opened at $0.51 on Friday. The stock has a 50-day moving average price of $0.72 and a two-hundred day moving average price of $1.25. Aptose Biosciences has a 1 year low of $0.40 and a 1 year high of $5.10. The stock has a market cap of $9.29 million, a PE ratio of -0.08 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15. On average, analysts forecast that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.